TCRX Dividend: TScan Therapeutics Inc Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

TCRX Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	8	2	21	13	10	1
Revenue Growth (YoY)	-11%	-90%	62%	30%	900%	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	33	30	26	20	13	6
Research & Development	121	107	88	59	44	20
Operating Expenses	158	137	114	80	58	27
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	-142	-127	-89	-66	-48	-26
Income Tax Expense	--	--	--	--	--	--
Net Income	-142	-127	-89	-66	-48	-26
Net Income Growth	28%	43%	35%	38%	85%	100%
Shares Outstanding (Diluted)	129.83	111.99	65.59	24.05	23.59	23.59
Shares Change (YoY)	9%	71%	173%	2%	0%	0%
EPS (Diluted)	-1.09	-1.13	-1.36	-2.75	-2.06	-1.11
EPS Growth	17%	-16%	-51%	34%	86%	91%
Free Cash Flow	-135	-114	-64	-70	-58	-7
Free Cash Flow Per Share	-1.03	-1.01	-0.97	-2.91	-2.45	-0.29
Gross Margin	--	--	--	--	--	--
Operating Margin	-1,862.5%	-6,700%	-442.85%	-507.69%	-480%	-2,600%
Profit Margin	-1,775%	-6,350%	-423.8%	-507.69%	-480%	-2,600%
Free Cash Flow Margin	-1,687.5%	-5,700%	-304.76%	-538.46%	-580%	-700%
EBITDA	-147	-130	-88	-61	-45	-25
EBITDA Margin	-1,837.5%	-6,500%	-419.04%	-469.23%	-450%	-2,500%
D&A For EBITDA	2	4	5	5	3	1
EBIT	-149	-134	-93	-66	-48	-26
EBIT Margin	-1,862.5%	-6,700%	-442.85%	-507.69%	-480%	-2,600%
Effective Tax Rate	--	--	--	--	--	--